Literature DB >> 9989927

Activation of the P2Z/P2X7 receptor in human lymphocytes produces a delayed permeability lesion: involvement of phospholipase D.

K C Fernando1, C E Gargett, J S Wiley.   

Abstract

Leukemic lymphocytes possess a cytolytic P2Z/P2X7 receptor which, when activated by extracellular ATP, opens a Ca2+- and Ba2+-permeable ion channel. This ATP-stimulated influx of divalent cations has been shown to activate an intracellular phospholipase D (PLD) which hydrolyzes membrane phosphatidylcholine. Lymphocytes that were exposed to ATP for 20 min at 37 degrees C, washed, and then incubated without ATP for 2 h showed an increased uptake of propidium2+, a dye widely used to measure cytotoxicity. The potent P2Z/P2X7 receptor inhibitor, KN-62, which is known to prevent the channel opening when added with ATP, did not block development of the permeability lesion when added 15 min before dye addition. The activity of lymphocyte PLD was stimulated fourfold by ATP and a proportion of this increased activity persisted for several hours after removal of ATP. Loading lymphocytes with intracellular choline+ by prior incubation of cells with ATP in isotonic choline chloride abolished both ATP-stimulated PLD activity and the ATP-induced permeability lesion. Addition of PLD but not phospholipase C to the extracellular medium increased lymphocyte permeability to propidium2+ and this effect was not observed in a choline medium. The cytolytic effect of exogenous PLD together with the inhibitory effect of choline, a product of the PLD reaction, suggests that sustained activation of intracellular PLD may be involved in the ATP-initiated cytolytic pathway. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9989927     DOI: 10.1006/abbi.1998.1045

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  9 in total

1.  ATP-induced [Ca(2+)](i) changes and depolarization in GH3 cells.

Authors:  H S Chung; K S Park; S K Cha; I D Kong; J W Lee
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

2.  Activation of the transcription factor FosB/activating protein-1 (AP-1) is a prominent downstream signal of the extracellular nucleotide receptor P2RX7 in monocytic and osteoblastic cells.

Authors:  Monica L Gavala; Lindsay M Hill; Lisa Y Lenertz; Maya R Karta; Paul J Bertics
Journal:  J Biol Chem       Date:  2010-09-02       Impact factor: 5.157

Review 3.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

4.  CAY10593 inhibits the human P2X7 receptor independently of phospholipase D1 stimulation.

Authors:  A Pupovac; L Stokes; R Sluyter
Journal:  Purinergic Signal       Date:  2013-06-21       Impact factor: 3.765

5.  P2X7 receptors regulate multiple types of membrane trafficking responses and non-classical secretion pathways.

Authors:  Yan Qu; George R Dubyak
Journal:  Purinergic Signal       Date:  2009-02-03       Impact factor: 3.765

6.  The P2X(7) receptor mediates the uptake of organic cations in canine erythrocytes and mononuclear leukocytes: comparison to equivalent human cell types.

Authors:  Ryan O Stevenson; Rosanne M Taylor; James S Wiley; Ronald Sluyter
Journal:  Purinergic Signal       Date:  2009-06-16       Impact factor: 3.765

7.  P2X7 receptor activates extracellular signal-regulated kinases ERK1 and ERK2 independently of Ca2+ influx.

Authors:  Jan Amstrup; Ivana Novak
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

Review 8.  The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?

Authors:  Luiz E B Savio; Paola de Andrade Mello; Cleide Gonçalves da Silva; Robson Coutinho-Silva
Journal:  Front Pharmacol       Date:  2018-02-06       Impact factor: 5.810

9.  Activation kinetics of single P2X receptors.

Authors:  Fritz Markwardt
Journal:  Purinergic Signal       Date:  2007-09-12       Impact factor: 3.765

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.